Clinical Research Trial Enrollment
Pharmaceutical Formulation of LSD for Anxiety
This study is investigating the effects of investigational MM120, a form of LSD (lysergic d–tartrate), on Generalized Anxiety Disorder (GAD). The sponsor of the study is Mind Medicine Inc. It features a study drug designated as a “breakthrough therapy”* by the FDA due to its promising past results. This study is conducted under strict medical supervision and participation is completely legal.
The first step to participating in this study is to complete a short pre-eligibility survey. Our team will review your responses and contact you with the next steps.
* When the FDA grants Breakthrough Therapy Designation to an investigational drug, it means the drug has shown preliminary clinical evidence that it may offer a significant improvement over existing treatments for a serious or life-threatening condition. This designation helps expedite development and review, providing the drug sponsor with increased FDA guidance and priority review to bring the treatment to patients faster.
If you know someone struggling with anxiety who may be interested in this opportunity, please share this with them.
Principal Investigator
Professor Emeritus, UCSD | Founder, Kadima Neuropsychiatry
This study is done at Kadima Neuropsychiatry Institute in La Jolla, CA
Clinical Trial Summary: A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating investigational MM120 Compared to Placebo in Generalized Anxiety Disorder – Voyage.
Read more about this study on ClinicalTrials.Gov